Other Titles
Screening and Surviving Breast Cancer: Promoting Health through Vigilance
Abstract
Session presented on Friday, July 24, 2015:
Purpose: The purpose of this study was to determine whether symptom burden differed according to survivor status (early [less than 3 years post completion of primary therapy], as opposed to long-term [years 3 through 5], survival) and/or use of endocrine or hormonal adjuvant therapy.
Methods: In this exploratory, cross-sectional study, data were collected on 133 survivors, using the MD Anderson Symptom Inventory, Karnofsky Performance Status, Charlson Comorbidity Index and a demographic/health history form. We analyzed symptom burden by survivor status and use of adjuvant therapy utilizing a 2-way ANOVA model.
Results: Patients who were prescribed endocrine or hormonal therapy had higher symptom severity and burden scores than did women who did not receive these therapies. No differences were noted in symptom burden, symptom severity and composite interference score between early- and long-term survivors. As functional status increased, the patients' symptoms scores decreased. Comorbidities did not impact symptoms.
Conclusions: Breast cancer survivors continue to experience symptoms, up to 6 years after completing primary therapy, but symptoms are more severe among those taking hormonal or endocrine therapy. Understanding the relationship between symptoms, cancer therapy, comorbidities, and functional status in early versus late survivorship may improve symptom management and outcomes for breast cancer survivors.
Sigma Membership
Unknown
Type
Presentation
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Breast Cancer, Survivorship, Symptom Burden
Recommended Citation
Strunk, Faith A.; Wood, Geri; Armstrong, Terri S.; Theriault, Richard L.; Urbauer, Diana L.; and Fellman, Bryan M., "Symptoms in breast cancer survivors who have completed primary therapy" (2016). INRC (Congress). 298.
https://www.sigmarepository.org/inrc/2015/presentations_2015/298
Conference Name
26th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
San Juan, Puerto Rico
Conference Year
2015
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Symptoms in breast cancer survivors who have completed primary therapy
San Juan, Puerto Rico
Session presented on Friday, July 24, 2015:
Purpose: The purpose of this study was to determine whether symptom burden differed according to survivor status (early [less than 3 years post completion of primary therapy], as opposed to long-term [years 3 through 5], survival) and/or use of endocrine or hormonal adjuvant therapy.
Methods: In this exploratory, cross-sectional study, data were collected on 133 survivors, using the MD Anderson Symptom Inventory, Karnofsky Performance Status, Charlson Comorbidity Index and a demographic/health history form. We analyzed symptom burden by survivor status and use of adjuvant therapy utilizing a 2-way ANOVA model.
Results: Patients who were prescribed endocrine or hormonal therapy had higher symptom severity and burden scores than did women who did not receive these therapies. No differences were noted in symptom burden, symptom severity and composite interference score between early- and long-term survivors. As functional status increased, the patients' symptoms scores decreased. Comorbidities did not impact symptoms.
Conclusions: Breast cancer survivors continue to experience symptoms, up to 6 years after completing primary therapy, but symptoms are more severe among those taking hormonal or endocrine therapy. Understanding the relationship between symptoms, cancer therapy, comorbidities, and functional status in early versus late survivorship may improve symptom management and outcomes for breast cancer survivors.